"Zalcitabine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication at low concentrations, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. Its principal toxic side effect is axonal degeneration resulting in peripheral neuropathy.
| Descriptor ID |
D016047
|
| MeSH Number(s) |
D03.383.742.680.245.500.950 D13.570.230.329.950 D13.570.230.500.925 D13.570.685.245.500.950
|
| Concept/Terms |
Zalcitabine- Zalcitabine
- Dideoxycytidine
- 2',3'-Dideoxycytidine
- 2',3' Dideoxycytidine
- ddC (Antiviral)
|
Below are MeSH descriptors whose meaning is more general than "Zalcitabine".
Below are MeSH descriptors whose meaning is more specific than "Zalcitabine".
This graph shows the total number of publications written about "Zalcitabine" by people in this website by year, and whether "Zalcitabine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 1 | 1 | 2 |
| 2001 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Zalcitabine" by people in Profiles.
-
Dalakas MC, Semino-Mora C, Leon-Monzon M. Mitochondrial alterations with mitochondrial DNA depletion in the nerves of AIDS patients with peripheral neuropathy induced by 2'3'-dideoxycytidine (ddC). Lab Invest. 2001 Nov; 81(11):1537-44.
-
Fischl MA, Richman DD, Saag M, Meng TC, Squires KE, Holden-Wiltse J, Meehan PM. Safety and antiviral activity of combination therapy with zidovudine, zalcitabine, and two doses of interferon-alpha2a in patients with HIV. AIDS Clinical Trials Group Study 197. J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Dec 01; 16(4):247-53.
-
Vanhove GF, Kastrissios H, Gries JM, Verotta D, Park K, Collier AC, Squires K, Sheiner LB, Blaschke TF. Pharmacokinetics of saquinavir, zidovudine, and zalcitabine in combination therapy. Antimicrob Agents Chemother. 1997 Nov; 41(11):2428-32.
-
Lewis W, Dalakas MC. Mitochondrial toxicity of antiviral drugs. Nat Med. 1995 May; 1(5):417-22.
-
Cupler EJ, Dalakas MC. Exacerbation of peripheral neuropathy by lamivudine. Lancet. 1995 Feb 18; 345(8947):460-1.
-
Jay C, Ropka M, Dalakas MC. The drugs 2',3'-dideoxyinosine (ddI) and 2',3'-dideoxycytidine (ddC) are safe alternatives in people with AIDS with zidovudine-induced myopathy. J Acquir Immune Defic Syndr (1988). 1994 Jun; 7(6):630-1.
-
Dubinsky RM, Yarchoan R, Dalakas M, Broder S. Reversible axonal neuropathy from the treatment of AIDS and related disorders with 2',3'-dideoxycytidine (ddC). Muscle Nerve. 1989 Oct; 12(10):856-60.
-
Dubinsky RM, Dalakas M, Yarchoan R, Broder S. Follow-up of neuropathy from 2',3'-dideoxycytidine. Lancet. 1988 Apr 09; 1(8589):832.